Clinical trials in ulcerative colitis: A Historical Perspective

Journal of Crohn's and Colitis

Volumn 9, Issue 7, 2015, Pages 580-588

  Hindryckx, Pieter ^a   Baert, Filip ^b   Hart, Ailsa ^c   Magro, Fernando ^d   Armuzzi, Alessandro ^e   Peyrin Biroulet, Laurent ^f  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b AZ Delta ^*  (Belgium)

^c ST MARK S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PORTO   (Portugal)

^e CATHOLIC UNIVERSITY   (Italy)

^f CHU NANCY BRABOIS   (France)

Author keywords

clinical trials; histological healing; history; mucosal healing; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; CORTISONE; CYCLOSPORIN A; GLUCOCORTICOID; MESALAZINE; METHOTREXATE; PLACEBO; SULFONAMIDE; TACROLIMUS; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE ASSESSMENT; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOLOGICAL TOLERANCE; INTERVENTION STUDY; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT CARE; PHARMACEUTICAL CARE; PLACEBO EFFECT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REMISSION; REVIEW; STUDY DESIGN; THERAPY EFFECT; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; COLONOSCOPY; HISTORY; MAINTENANCE CHEMOTHERAPY; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; COLONOSCOPY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MAINTENANCE CHEMOTHERAPY; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84963716558     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv074     Document Type: Review

References (85)

1. Aretaeus. The Extant Works of Aretaeus, The Cappadocian. Adams F, editor. Boston: Milford House; 1972 (republication of the 1856 edition)
2. Wilks S. Morbid appearances in the intestine of Miss Bankes. London Medical Gazette 1859;2:264
3. Crohn BB, Ginzberg L, Oppenheimer G. regional ileitis, a pathologic and clinical entity. JAMA 1932;99:1323-9
4. Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol 2014;12:1793-1800
5. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356-63
6. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477-83
7. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014;12:929-34
8. De Dombal FT. Ulcerative colitis: definition, historical background, aetiology, diagnosis, natural history and local complications. Postgrad Med J 1968;44:684-92
9. Svartz N. Salazopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic effects in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparations. Acta Med Scand 1942;110:580-98
10. Svartz N. The treatment of 124 cases of ulcerative colitis with salazopyrin. Attempts at desensitization in cases of hypersensitiveness to sulphasalazine. Acta Med Scand 1948;131:465-72
11. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000543
12. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med 1950;85:545-666
13. Dutoit CH. The treatment of chronic idiopathic ulcerative colitis with adrenocorticotrophic hormone. J Clin Invest 1950;29:809-10
14. Rossmiller HR, Brown CH, Ecker JA. The effect of ACTH on nonspecific ulcerative colitis. Gastroenterology 1951;17:25-7
15. Palmer WL, Kirsner JB. Observations on the influence of corticotropins upon the course of chronic ulcerative colitis. Trans Am Clin Climatol Assoc 1954;66:10-7
16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Br Med J 1955;2:1041-8
17. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CW, Jones FA. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960;1:217-22
18. Lennard-Jones JE, Baron JH, Connell AM, Jones FA. A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Gut 1962;3:207-10
19. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013;7:1-33
20. Baron JH, Connell AM, Lennard-Jones JE, Jones FA. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962;1:1094-6
21. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5
22. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000543
23. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5
24. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35
25. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9
26. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31
27. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62
28. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21
29. Kozarek RA. Methotrexate and ulcerative colitis: wrong drug? Wrong dose? Or wrong disease? Gastroenterology 1996;110:1652-6
30. Mañosa M, García V, Castro L, et al. Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. J Crohns Colitis 2011;5:397-401
31. Carbonnel F, Colombel JF, Filippi J, et al. Methotrexate for corticosteroiddependent ulcerative colitis: results of a placebo randomized controlled trial. In: ECCO congress 2015; Barcelona. Oral presentation 023
32. Bakke JL. Outline of undesirable effects of ACTH and cortisone. Northwest Med 1951;50:930-3
33. Truelove SC and Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1959;1:387-94
34. Lennard-Jones JE, Misiewicz JJ, Connell AM, Baron JH, Jones FA. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965;1:188-9
35. Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Avery Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8
36. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 1973;14:923-6
37. Riis P, Anthonisen P, Wulff HR, Folkenborg O, Bonnevie O, Binder V. The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. Scand J Gastroenterol 1973;8:71-4
38. Schwartz R, Dameshek W. Drug-induced immunological tolerance. Nature 1959;183:1682-3
39. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962;49:592-3
40. Mackay IR, Wall AJ, Goldstein G. Response to azathioprine in ulcerative colitis. Report of 7 cases. Am J Dig Dis 1966;11:536-45
41. Bowen GE, Irons GV Jr, Rhodes JB, Kirsner JB. Early experiences with azathioprine in ulcerative colitis; a note of caution. JAMA 1966;195:460-4
42. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on a controlled therapeutic trial. Br Med J 1974;4:627-30
43. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-2
44. El-Matary W, Vandermeer B, Griffiths AM. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2009;3:CD007560
45. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-8
46. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002
47. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
48. European Medicines Agency. Guideline on the development of new medicinal products for the treatment of ulcerative colitis. CHMP/EWP/18463/2006. London: European Medicines Agency; 2008
49. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909-15
50. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
51. Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65
52. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology 2014;146:85-95
53. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109
54. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400
55. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
56. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710
57. Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007;132:516-26
58. Peyrin-Biroulet L. Deep remission in Crohn's disease: is it the end of the placebo effect? Clin Gastroenterol Hepatol 2013;12:347
59. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2013;133:1099-105
60. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11
61. European Medicines Agency. Concept paper on the revision of the guideline on the 4 development of new medicinal products for the treatment 5 of ulcerative colitis (CHMP/EWP/18463/2006). EMA/CHMP/327812/2014. London: European Medicines Agency; 2014
62. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86
63. Samaan MA, Mosli MH, Sandborn WJ, et al. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis 2014;20:1465-71
64. Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am 2014;24:367-78
65. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009;137:1934-43
66. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145:149-57
67. Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y) 2012;8:29-38
68. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013;15:315
69. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201
70. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966;11:847-57
71. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-8
72. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099-105
73. Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment for inflammatory bowel disease, from clinical trials and practice. Gastroenterology 2014;148:37-51
74. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9
75. Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014;8:1582-97
76. Bressenot A, Salleron J, Bastien C, et al. Comparing histological activity indexes in UC. Gut 2014. doi: 10.1136/gutjnl-2014-307477. [Epub ahead of print]
77. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7
78. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8
79. Khanna R, Levesque BG, Bressler B, et al. Early combined immunosuppression for the management of Crohn's disease: a community-based cluster randomized trial. In: ECCO Congress, Copenhagen; 2014. Oral presentation OP4
80. Gottlieb S. The FDA Should Not Mandate Comparative-Effectiveness Trials 2011. http://www.aei.org/outlook/health/medical-technology/fda/thefda-should-not-mandate-comparative-effectiveness-trials/
81. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8
82. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1246-56
83. Khanna R, Zou G, D'Haens G, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther 2014;41:77-86. doi: 10.1111/apt.13001. [Epub ahead of print]
84. US Department of Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79
85. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues (EMA/CHMP/BMWP/403543/2010). London: European Medicines Agency; 2012